What is Piramal Structured Credit Opportunities Fund's investment strategy?
Piramal Structured Credit Opportunities Fund is covered in Rupeia's private credit research universe. The current public record describes the strategy as Performing and structured private credit; growth and special situations, with a sector focus of Healthcare and pharmaceuticals, technology, financial services, industrials. The profile should be read with the linked source trail and Typical route: Category II AIF context.
What portfolio evidence is available for Piramal Structured Credit Opportunities Fund?
The profile displays only company or asset names attributable to Piramal Structured Credit Opportunities Fund in the reviewed public sources: Biodeal Pharmaceuticals; Transaction Solutions International; Nihilent; Neelkanth Subh Ashish Exim. It does not represent a complete current portfolio unless the manager has published one.
What is known about Piramal Structured Credit Opportunities Fund's performance or track record?
Biodeal Pharmaceuticals reported in July 2026 that its ₹110 crore investment from Piramal Structured Credit Opportunities Fund was fully redeemed after a reported 20%+ IRR. Nihilent separately identified the fund as a financing provider in its 2023 acquisition transaction. Fund-level audited net returns and distributions are not publicly disclosed. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.
What are Piramal Structured Credit Opportunities Fund's fund size, fees and minimum investment?
Public fund size: Fund-level corpus is not publicly disclosed. Piramal’s 2024–25 annual report and manager materials confirm the AIF vehicle and its sponsor/manager relationship.. Public terms or access information: Category II AIF; structured credit, growth capital, acquisition financing and special-situation funding; vehicle-level tenure, fees, carry, hurdle, recycling and investor waterfall terms are not publicly disclosed.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
Who is on Piramal Structured Credit Opportunities Fund's investment team?
The current source record names Kalpesh Kikani (CEO, Piramal Alternatives); Abhishek Jain (Co-Head, Performing Credit Fund); Anant Khatri (Co-Head, Performing Credit Fund). Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
What risks should be reviewed before investing with Piramal Structured Credit Opportunities Fund?
Review borrower concentration, security and seniority, cash versus accrued income, defaults, recoveries, fund leverage and liquidity. The current open diligence point is: Public disclosures identify several fund-attributed investments and a 2026 Biodeal exit, but do not disclose a complete current portfolio schedule, audited fund-level net returns, DPI, TVPI, fees, carry or current NAV..
What is the latest public update on Piramal Structured Credit Opportunities Fund?
2026-07-29: Biodeal Pharmaceuticals announced on 2026-07-29 that its ₹110 crore investment from Piramal Structured Credit Opportunities Fund, made in 2024, was fully redeemed and generated a reported 20%+ IRR. Piramal’s current public site continues to list the fund as a performing-credit vehicle.
